[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Vincerx Pharma, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":53},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100518725","phase-1-study-of-vip943-in-subjects-with-advanced-cd123-hematologic-malignancies-100518725",false,"NCT06034275","Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies","An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity, Pharmacokinetics, and Pharmacodynamics of VIP943 Monotherapy in Subjects With Advanced CD123+ Hematologic Malignancies","Inclusion Criteria:\n\n* Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.\n* Evidence of ≥5% bone marrow or blood blasts (acute leukemia) or ≥5% bone marrow or blood myeloblasts (MDS) to allow for assessment of drug activity.\n* Evidence of CD123 expression from a local laboratory.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n\nExclusion Criteria:\n\n* Known central nervous system (CNS) metastases and\u002For carcinomatous meningitis.\n* Clinically significant cardiac disease including congestive heart failure \\> New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.","ALL","18 Years",{"count":19,"type":20},36,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies",[26,27,28],"Acute Myeloid Leukemia","B-cell Acute Lymphoblastic Leukemia","High-risk Myelodysplastic Syndrome",[30,31,32,33,34,35,36,37,38,39],"ADC","Hematologic Malignancies","Leukemia","CD123","B-ALL","AML","MDS","Relapsed\u002F Refractory","Hematologic Diseases","Bone Marrow Diseases","RECRUITING","2024-11-13",{"date":43,"type":44},"2024-11-15","ACTUAL",{"date":46,"type":44},"2023-09-13",{"date":48,"type":20},"2025-12-31",{"name":50,"class":51},"Vincerx Pharma, Inc.","INDUSTRY",5,""]